RecruitingPhase 2Phase 3NCT06248710

Dog Presence and Oxytocin on Trust Towards Therapists

Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs: A Randomized Controlled Trial in Healthy Adults


Sponsor

Dr. Karin Hediger

Enrollment

176 participants

Start Date

Jan 29, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Oxytocin has been proposed as a neuroendocrine mechanism that may mediate the relationship between dog ownership and positive health outcomes and be linked to human-dog interactions and is thought to be a mechanism of interspecies bonding. While the role of oxytocin in human bonding behaviours and social behaviour, in general, is becoming well-established the role of oxytocin in human-animal interaction and Animal-Assisted Interventions (AAI) remains unclear. This research gap calls for more high-quality research investigating this possible neuroendocrine underlying mechanism to advance knowledge about AAI. If oxytocin indeed might be involved in interspecies bonding, intranasally administered oxytocin should not only enhance trust toward a human but also towards a dog.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age ≥ 18 years
  • Signed informed consent

Exclusion Criteria9

  • Pregnancy
  • Being scared of dogs or dog hair allergy by self-report
  • Any acute or chronic disease (e.g., chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes, respiratory disease, skin pathologies etc.)
  • Current medications (psychoactive medication, narcotics, intake of analgesics) or being currently in psychological or psychiatric treatment
  • Drug consumption (THC, cocaine, heroin, etc.) within the past 24h before study appointment
  • Ongoing psychotherapy treatment
  • Sexual Intercourse within the past 24h before study appointment
  • Current disease involving respiratory system (e.g., influence, asthma etc.)
  • Insufficient German language skills to understand the instructions

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOxytocin nasal spray

Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant

OTHERAnimal-Assisted Intervention

The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.

DRUGPlacebo

The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.


Locations(1)

University of Basel

Basel, Canton of Basel-City, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06248710


Related Trials